Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Apr 13, 2015-- Data to Highlight Impact of H3's Splicing Modulation Platform --
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, announced today that it will present a series of posters at the...
-
Mar 30, 2015Clinical Study (003-011) to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD)
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in a randomized, double-blind study of farletuzumab in first-relapsed, platinum-sensitive...
- Feb 27, 2015A New Drug Approved for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Eisai Inc. announced today that LENVIMA™ (lenvatinib), a receptor tyrosine kinase inhibitor, is now available through two specialty pharmacies, Accredo and Biologics, Inc. LENVIMA is indicated...
-
Feb 25, 2015Eisai Demonstrates Commitment to Patients with Rare Cancers
Eisai Inc. today announced that eribulin met the primary endpoint in its Phase 3 trial (Study 309), demonstrating a statistically significant improvement in overall survival (OS) in patients with...
-
Feb 13, 2015- New Therapy Demonstrated a Dramatic Improvement in Progression-Free Survival and a Statistically Significant Overall Response Rate in Some Patients with RAI-Refractory Differentiated Thyroid Cancer
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the company's receptor tyrosine kinase inhibitor LENVIMA™ (lenvatinib) for the treatment of locally recurrent...
